A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.
- EligibilityCriteria: Inclusion Criteria:  Male or female, ≥ 18 and ≤ 70 years old at the time of screening BMI ≥ 32 and ≤ 40 kg/m² at screening  Exclusion Criteria:  Known history of any form of diabetes mellitus, or HbA1c ≥6.5% (48 mmol/mol) Participants who have had an increase or decrease in body weight more than 5% within the last 3 months Treated with any prescription medication or procedure that promotes weight loss or weight gain in the last 6 months Use of any drug treatment that affects gastric pH Use of any drug treatment that affects gastrointestinal motility Diagnosis or treatment of any symptomatic or structural abnormality of the GI tract or active disease within 12 months Clinically significant symptoms (as determined by the Investigator) of nausea, vomiting, bloating, diarrhea, flatulence, constipation, or abdominal pain in the last 30 days - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult